|
|
Dizziness … light-headedness … fainting … falls …
Do these symptoms severely limit your daily activity?
Help us investigate a medication that may help people with NOH get back on their feet. CLICK HERE to find out what you need to know.
|
| To view a map of all participating sites, CLICK HERE. |
|
 |
|
Are you afraid to rise and shine? You may qualify to participate in research into an investigational treatment option.
Though we may not always enjoy getting out of bed in the morning, for most people it’s nothing to be afraid of. However, for people with Neurogenic Orthostatic Hypotension (NOH), dizziness and possible fainting upon standing can make “rise and shine” a frightening time.
Answers to your questions about NOH
What is NOH?
NOH is a condition that is frequently seen in patients with neurological diseases like Parkinson’s disease (PD), multiple system atrophy (MSA) and pure autonomic failure (PAF).
What are the symptoms?
Upon standing, those with NOH experience dizziness, light-headedness and fainting that can lead to falls.
What causes NOH?
NOH symptoms are thought to be the result of depleted levels of norepinephrine, which leads to a drop in blood pressure and decreased blood flow to the brain on standing.
How is NOH treated?
Currently available treatment options provide some relief for some people, but are not always effective and may be accompanied by severe side effects that limit their usefulness. Support garments (tight-fitting leotards) may prove useful in some subjects, but may be difficult to put on without family or nursing assistance, especially for older subjects. Proamatine® (midodrine), Florinef® (fludrocortisone) and ephedrine are some of the drugs that have been used to treat orthostatic hypotension, although only midodrine is specifically approved for this indication. The limitations of currently available treatments, as well as the incapacitating and often progressive nature of the condition, all point to the need for an improved treatment alternative.
What is the purpose of the NOH study?
This study will investigate the effectiveness of Droxidopa in treating symptoms of NOH in patients with primary autonomic failure (pure autonomic failure, multiple system atrophy, Parkinson’s disease), non-diabetic neuropathy or Beta Hydroxylase deficiency. The investigational medication, Droxidopa, is believed to enhance norepinephrine levels in the body leading to more stable blood pressure and blood flow to reduce the dizziness and fainting suffered by people with NOH.
How can I join the search for a better quality of life?
You or someone you know may qualify to participate in this study based on:
- Diagnosis of NOH
- Current use of either Proamatine® (midodrine) or Florinef® (fludrocortisone)
- Suspicion of NOH due to repeated dizziness, light-headedness or fainting when standing.
Participation in the study may aid in the effort to improve the quality of life for people with NOH.
Find out if you qualify
Access our preliminary online screening questionnaire.
Study participants who currently take ephedrine or Proamatine® (midodrine) must stop taking these medications at least two days before beginning the study medication. Other criteria may also exclude participation.
Help us stand up to NOH
Every research participant is important in the search for effective and safe medications that may lead to a new day in the treatment of NOH.
Those who qualify to participate in this research will receive study medication (or a placebo), study-related medical testing and other associated screenings at no cost. Study participants for whom the investigational medication is effective in relieving NOH symptoms can continue to receive the medication at no cost following participation in the study. Participants may be compensated for travel expenses and accommodations.
|
|
|
|
